Genomic data is presented at EHA. Onconova's main focus is the pivotal INSPIRE study, assessing rigosertib in the 2nd-line high-risk myelodysplastic syndrome (HR-MDS) patients. The company presented genomic data at the baseline from 190 patients enrolled in this study.Future genomic data will be meaningful for the rigosertib clinical response. The baseline patient mutational profile showed that RAS pathway mutations were observed more commonly in patients that progressed on hypomethylating agents (HMA) therapy versus patients that failed HMA therapy. These results set the mutational profile for the patients prior to study treatment. The mutational analysis after the treatment will provide further information on the clinical responses of rigosertib.Read More >>